Concepedia

Toby Kent

TK

12

Publications

489

Citations

10

H-Index

2002

Active since

Affiliations

Novartis (United Kingdom)(Current)

University of Kent

Novartis (Switzerland)

University of Nottingham

Toby Kent is an author at Novartis (United Kingdom) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

2002–2020

12

Publications

12

The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium

David A. Sykes, Mark R. Dowling, Juliet Leighton-Davies et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 120 citations

Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action

ME Bradley, Bruno Dombrecht, Jodie Manini et al. · Molecular Pharmacology · 2014 · 87 citations · Full text

The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35

Amanda E. Mackenzie, Gianluigi Caltabiano, Toby Kent et al. · Molecular Pharmacology · 2013 · 67 citations · Full text

Quantitative GPCR and ion channel transcriptomics in primary alveolar macrophages and macrophage surrogates

Paul J. Groot‐Kormelink, Lindsay Fawcett, Paul D. Wright et al. · BMC Immunology · 2012 · 50 citations · Full text

Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey

Toby Kent, A Davidson, Daniel S. Newman et al. · Lupus · 2017 · 40 citations

, , +18

Rows per page

1–5 of 12